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CONSENSUS
STATEMENT

E X P E RT C O N S E N S U S D O C U M E N T

The International Scientific Association
for Probiotics and Prebiotics (ISAPP)
consensus statement on the definition
and scope of prebiotics
Glenn R. Gibson1, Robert Hutkins2, Mary Ellen Sanders3, Susan L. Prescott4,
Raylene A. Reimer5, Seppo J. Salminen6, Karen Scott7, Catherine Stanton8,
Kelly S. Swanson9, Patrice D. Cani10, Kristin Verbeke11 and Gregor Reid12

Abstract | In December 2016, a panel of experts in microbiology, nutrition and clinical research
was convened by the International Scientific Association for Probiotics and Prebiotics to review
the definition and scope of prebiotics. Consistent with the original embodiment of prebiotics,
but aware of the latest scientific and clinical developments, the panel updated the definition of a
prebiotic: a substrate that is selectively utilized by host microorganisms conferring a health
benefit. This definition expands the concept of prebiotics to possibly include non-carbohydrate
substances, applications to body sites other than the gastrointestinal tract, and diverse categories
other than food. The requirement for selective microbiota-mediated mechanisms was retained.
Beneficial health effects must be documented for a substance to be considered a prebiotic. The
consensus definition applies also to prebiotics for use by animals, in which microbiota-focused
strategies to maintain health and prevent disease is as relevant as for humans. Ultimately, the goal
of this Consensus Statement is to engender appropriate use of the term ‘prebiotic’ by relevant
stakeholders so that consistency and clarity can be achieved in research reports, product
marketing and regulatory oversight of the category. To this end, we have reviewed several aspects
of prebiotic science including its development, health benefits and legislation.
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Improving human health through modulation of the
microbiome is an evolving strategy that is part of a
comprehensive, holistic approach to lifestyle wellness1.
The rich, diverse microbial ecosystems inhabiting
mucosal and cutaneous surfaces provide targets for
approaches to maintain or improve health or to treat
disease. The ability to shift the composition and meta
bolic signatures of these microbial populations is now
possible, via dietary or non-dietary interventions2,3.
Over 20 years ago, a class of compounds, termed
prebiotics, were recognized for their ability to manipu
late host microbiota to the benefit of the host 4. At that
time fructans (fructooligosaccharides (FOS) and inulin)
and galactans (galactooligosaccharides or GOS) fit that
category, with their effects acting through enrichment
of Lactobacillus and/or Bifidobacterium spp. FOS and
GOS currently dominate the prebiotic category as evi
denced by numerous studies on their prebiotic effects.

Today, the prebiotic concept has expanded, in part,
because of advances in tools for microbiome research
(for example, high-throughput sequencing), which
have improved our knowledge of the composition of
the microbiota and enabled identification of additional
substances influencing colonization. Concurrent with
this progress is the realization that a broader range of
beneficial microorganisms are affected by prebiotics
and also that they might be effective at extraintestinal
sites directly or indirectly 5. Furthermore, the use of
prebiotics has expanded to production and companion
animals6,7 and categories beyond food. Accordingly,
researchers have advocated for reconsideration of the
contemporary nature of prebiotics, which formed
the aim of the consensus panel that was convened on
9 December 2016 in London, UK. The various aspects
looked at in this review of evidence were: evolution of
the term prebiotic; effects and selectivity; substrates that
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are prebiotics; metabolism of prebiotics; host benefits;
companion animals; and guidance for producers, con
sumers and regulators. Herein, the term ‘microbiota’
refers to the collection of microorganisms in an eco
system and ‘microbiome’ when genetic elements are
also considered.

Methods
A panel of experts was organized by the board of direc
tors of the International Scientific Association for
Probiotics and Prebiotics (ISAPP), a non-profit collab
oration of scientists dedicated to advancing scientific
excellence in probiotics and prebiotics. ISAPP activ
ities are determined by the board of directors, compris
ing global academic scientists. Through its Industry
Advisory Committee, ISAPP incorporates indus
try scientists in its activities and raises funds to advance
its mission. However, no input into this consensus
panel process was provided by members of the Industry
Advisory Committee. ISAPP functions as an indepen
dent, objective, science-based voice for the probiotic and
prebiotic fields.
Panellists included experts involved with the original
development of prebiotics and subsequent modifications
of the definition. Specialties included microbiology,
nutrition, biochemistry and clinical research in both
humans and animals. To prepare, panellists developed a
discussion outline and target questions. Several delivered
brief presentations that addressed background and core
issues. Discussion ensued for each issue until consensus
was achieved. After the meeting, individual panellists
wrote sections of the summary, which were compiled
by G.R.G., M.E.S and G.R. into a draft report. This docu
ment was edited and agreed upon by all panel members,
and finally by the ISAPP board of directors.

Evolution of the term prebiotic
In 1921, Rettger & Cheplin8 described experiments with
humans whose microbiota were enriched with lactobacilli
following consumption of carbohydrates. The finding that
the colon was dominated by a naerobes, many of which
obtain energy by fermenting substrates from the diet 9,10,
initiated research that played an important foundational
part in many s ubsequent microbiome projects.
Although dietary oligosaccharides had long been
used to impart health benefits, principally in Asia, the
prebiotic concept was first defined in 1995 as a “non-
digestible food ingredient that beneficially affects the
host by selectively stimulating the growth and/or activity
of one or a limited number of bacteria already resident in
the colon” (REF. 4). The prebiotic concept was initiated to
build on the probiotic concept, the most widely accepted
definition of which was proposed in 2001 (REF. 11) and
reaffirmed in 2014 (REF. 12). Prebiotics target human-
associated and animal-associated microbiota with the
goal of improving health. Whereas probiotics use live
microorganisms, prebiotics are non-viable substrates
that serve as nutrients for beneficial microorganisms
harboured by the host, including administered probiotic
strains and indigenous (resident) microorganisms. Thus,
prebiotics differ from most dietary fibres such as p
 ectins,
cellulose and xylans, which encourage growth of a wide
variety of gut microorganisms. Our meaning here is
that a prebiotic should not be broadly metabolized, but
elicit a metabolism biased towards health-promoting
microorganisms within the indigenous ecosystem. The
review by Simpson and Campbell13 provides an overview
of microbiota interactions and compares studies on fibre
and prebiotics, concluding that prebiotics (particularly
FOS and GOS) seem to promote increased abundance
of bifidobacteria within the gut microbiota.
Most of the first prebiotics assessed in humans and
used commercially were shown to stimulate Lactobacillus
and Bifidobacterium specifically, but not pathogens
such as certain members of the Clostridia class and
Escherichia coli 14–16. As these genera were commonly
used as probiotics, this approach provided a commonal
ity between probiotics and prebiotics. Thus, the prebiotic
definition and the concept itself became imprinted in
food, nutrition and microbiology fields17. In 2004, the
definition of prebiotics was altered to “selectively fer
mented ingredients that allow specific changes, both in
the composition and/or activity in the gastrointestinal
microflora that confers benefits upon host well-being
and health” (REF. 18). As per this definition, three c riteria
were required for a prebiotic: the ability to resist host
digestion (for example gastric acidity, hydrolysis by
mammalian enzymes and gastrointestinal absorption);
that they are fermented by intestinal microorganisms;
and that they selectively stimulate the growth and/or
activity of intestinal bacteria associated with health and
well-being. Thus, it was implicit that trials to demon
strate prebiotic effects should be performed in the target
host. In vitro assessments designed to identify pathways
or mechanisms would not confirm prebiotic status in the
absence of studies p
 roviding evidence of health effects
in the host.
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However, as prebiotic concepts evolved, so too did
their application to extraintestinal sites. The Food and
Agricultural Organization (FAO) of the United Nations
(UN) organized a Technical Meeting to update the defin
ition of prebiotics in 2008. This panel proposed that
prebiotics be redefined as “a non-viable food component
that confers a health benefit on the host associated with
modulation of the microbiota” (REF. 19). Here, selective
fermentation was removed as a criterion, but in doing
so the definition was criticized for not excluding anti
biotics. Gibson et al.20, 2 years later, defined the narrower
category of ‘dietary prebiotics’ as “a selectively fermented
ingredient that results in specific changes in the compo
sition and/or activity of the gastrointestinal microbiota,
thus conferring benefit(s) upon host health”.
In 2015, Bindels et al.21 proposed that specificity
requirements should be removed on the basis of reports
showing that multiple taxa, rather than particular species,
were enriched by prebiotics22. This proposal led to another
definition of a prebiotic as “a non-digestible compound
that, through its metabolization by microorganisms in
the gut, modulates the composition and/or activity of the
gut microbiota, thus, conferring a beneficial physiological
effect on the host” (REF. 21). This definition limited pre
biotics to interactions with the gut microbiota (excluding
extraintestinal sites such as vagina and skin) and removed
the requirement for selective fermentation. Selectivity
with respect to microbial fermentation is viewed by this
panel as key to the prebiotic concept. Importantly, how
ever, this definition emphasized the functional effects of
prebiotics on the microbiota.
Given the proposed definitions already described, as
well as others, the need for a consensus definition was evi
dent23. This need was amplified by views that the prebiotic
concept required clarification on specificity, mechanisms
of effect, health attributes and relevance, with some authors
being critical of concepts already put forward and its
approaches24–26. Thus, the current ISAPP consensus panel
Box 1 | Main conclusions of the consensus panel regarding prebiotics
• The definition of a prebiotic has been modified to ‘a substrate that is selectively
utilized by host microorganisms conferring a health benefit’
• Although most current prebiotics are administered orally, they can also be administered
directly to other microbially colonized body sites, such as the vaginal tract and skin
• Health effects of prebiotics are evolving but currently include benefits to the
gastrointestinal tract (for example, inhibition of pathogens, immune stimulation),
cardiometabolism (for example, reduction in blood lipid levels, effects upon insulin
resistance), mental health (for example, metabolites that influence brain function,
energy and cognition) and bone (for example, mineral bioavailability), among others
• We acknowledge that definitive proof of causality is difficult to provide. However,
a human or animal study showing a change in heath markers or symptoms after a
specific influence on the microbial population (that is, a blinded placebo-controlled
trial with appropriate exclusion and/or inclusion criteria) then it is reasonable to
assume that the two are causally related
• Currently established prebiotics are carbohydrate-based, but other substances such
as polyphenols and polyunsaturated fatty acids converted to respective conjugated
fatty acids might fit the updated definition assuming convincing weight of evidence
in the target host
• The beneficial effect(s) of a prebiotic on health must be confirmed in the target animal
for its intended use and mediated through the microbiota

now proposes the following definition of a prebiotic:
a substrate that is selectively utilized by host micro
organisms conferring a health benefit (BOX 1). See BOX 2
for additional rationale used to adopt this new definition.

Prebiotic effect and selectivity
Prebiotics are not the only substances that can affect the
microbiota10 (FIG. 1). The criterion of selective utilization
distinguishes prebiotics from many of these other sub
stances16. Hopefully, the new definition will readily e nable
a developer to know whether a new substrate fits the
prebiotic category.
In previous iterations of the term prebiotic, ‘selec
tively’ was interpreted as referring mostly to lactobacilli
and bifidobacteria. Specific stimulation of bifidobacteria
(bifidogenesis) was considered a prebiotic effect. Early
research on gut microbial ecology was based on culture
methods, which we now know were insufficient to reveal
the complexity of prebiotic-induced microbial changes.
Molecular-based methods, which have since identified a
broader range of members of the gut microbial commu
nity, have enabled the appreciation that more bacterial
genera might utilize some prebiotic substrates, by fermen
tation and other metabolic pathways. These microorgan
isms can vary depending upon the host and ecosystem
under consideration. Hence, it is recognized today that
prebiotic effects probably extend beyond bifidobacteria
and lactobacilli, but to meet the selectivity criterion of
a prebiotic, the range of microorganisms affected must
be limited. To this end, in two human studies that used
high-throughput sequencing, bifidobacteria responded
to prebiotic use22,27. However, other groups such as
Faecalibacterium prausnitzii also increased in abundance
in one trial22 and in another study Anaerostipes spp. were
additionally elevated, whereas Bilophila spp. decreased27.
Both studies used high-throughput sequencing to confirm
selectivity of the prebiotic fermentation. Selectivity does
not necessarily mean effects on just one microbial group;
a selective effect could extend to several microbial groups,
just not all. A prebiotic, in addition to having a selective
effect on microorganisms, must also evoke a net health
benefit. The guiding principles are that microorganisms
affected and metabolites produced are c onsidered to be
beneficial and linked to a defined health aspect.
Envisaging every scenario is challenging. But, for
example, is a product a prebiotic if its intake increases
microbial production of butyrate? Short-chain fatty
acids (SCFAs), such as acetate, propionate and butyrate,
and some other compounds, are recognized as having
mechanistic links to health outcomes28,29. If the effect is
a measurable benefit to host health, distinct from a con
trol, it would constitute a ‘prebiotic effect’. To verify that
the product itself is prebiotic, experiments would have
to demonstrate that the product is selectively utilized,
in this case by showing that a defined range of butyrate-
producing microorganisms grow because of the product.
Alternatively, the product might stimulate growth of other
members of the microbiota, releasing metabolites that in
turn stimulate butyrate production by other microorgan
isms. This phenomenon could constitute a ‘cross-feeding
effect’. The net result is still selective in that propagation of
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particular microorganisms led to this overall health effect.
However, if pathogenic microorganisms are involved in
butyrate generation and a negative consequence occurs
for the host, then it cannot be termed a prebiotic. This
distinction makes it important to determine both function
and composition of the gut microbiota involved.
Similarly, prebiotics for use in the gut microbiota of
humans should not form gas distension issues after inges
tion; as such, their fermentation must be selective and
preferably include genera that are not gas formers (such
as Clostridium). This consideration points unequivo
cally towards the need for selective metabolism. Notably,
neither bifidobacteria nor lactobacilli manufacture gas
in their metabolism16.
Moreover, it is implicit that such influences on host
health be determined in mixed microbial ecosystems
containing the full microbiota of interest (that is, in vivo).
Making inferences on prebiotic effects from pure or
co‑culture experiments is inadequate. Similarly, any
conclusion regarding prebiotic activity must be based
on an assessment of the full microbial diversity, not
simply increased abundance of gut bifidobacteria or
lactobacilli, for example. The best techniques available
need to applied, particularly as the microbiome field
has benefited greatly from molecular-based techno
logical advances. These techniques would include high-
throughput sequencing, including metagenomics, which
demonstrates quantifiable changes in the microbiota.

Box 2 | Justification for the new definition of prebiotics
• It is a straightforward definition that avoids unnecessary technical jargon.
• It clarifies that prebiotic targets extend beyond stimulation of bifidobacteria
and lactobacilli, and recognizes that health benefits can derive from effects on
other beneficial taxa including (but not limited to) Roseburia, Eubacterium or
Faecalibacterium spp.
• The term ‘substrate’ was chosen for its meaning of a substance on or from which
an organism obtains its nourishment (for example, through fermentative breakdown
of the substrate). This term aligns with the word ‘utilized’ and implies ‘for growth
through nourishment’, therefore excluding viable microorganisms and antimicrobial
agents as prebiotics.
• Prebiotics rely upon microbial metabolism. Non-microbial effects do not fit with our
current classification. For the latter, these effects have tended to be researched in
situations in which a resident microbiota is devoid or compromised. To confirm
prebiotic traits, studies in the same species as the intended use are required.
• Prebiotics require selective utilization by live host microorganisms, not simply enzymes
or bioactive chemicals, in a manner that sustains, improves or restores host health.
Although many microorganisms might be able to breakdown a given substrate, it is the
resultant health benefit to the host owing to selective utilization by microorganisms
that enables it to be termed prebiotic. The actual mechanism of conferring benefit
might also be mediated by microbial metabolic products. As such, both the microbiota
changes and metabolites should be investigated, together with health outputs.
• It allows a prebiotic to invoke changes to any host microbial ecosystem, not just the
gut. However, dietary prebiotics should still be non-digested by the host but utilized
by the microbiota.
• Both prebiotic safety and use at appropriate dose are implicit in this definition.
An appropriate dose must be sufficient to generate a prebiotic effect, but not too
high to induce unwanted or adverse effects such as excessive gas formation or
non-selective utilization. The ‘adequate’ dose will vary depending upon the microbial
ecosystem and associated metabolic effects.
• Demonstration of health benefits in well-controlled studies in the target host is required.

Similarly, metabonomic assessments, such as NMR or
mass spectrometry, in appropriate biological materials
can identify metabolic responses to prebiotics and help
determine concomitant functionality of the microbiota.

Substrates that are prebiotics
A number of fermentable carbohydrates have been
reported to convey a prebiotic effect, but the dietary pre
biotics most extensively documented to have health bene
fits in humans are the non-digestible oligosaccharides
fructans and galactans30. These oligosaccharides are
preferentially metabolized by bifidobacteria16. A phenom
enon explained by structure to function relationships; the
linkage bonds in FOS and GOS can be readily degraded by
degraded by β
 ‑fructanosidase β
 ‑galactosidase enzymes,
respectively, which are prevalent in bifidobacteria. This
genus also seems to preferentially metabolize the chain
length size typical of oligosaccharides; that is, a degree
of polymerization (DP) between 4 and 30 (REFS 31,32).
Importantly, having the appropriate transport machinery
to capture and deliver these substrates into the microbial
cytoplasm is a key requirement and contributes to the
selectivity of prebiotics in the target sites33 and empha
sizes their ability to do so in a competitive environment in
mixed culture ecosystems such as the human gut.
Substrates that affect composition of the microbiota
through mechanisms not involving selective utilization
by host microorganisms are not prebiotics. These sub
strates would include antibiotics, minerals, vitamins
and bacteriophages, which are not growth substrates,
even though their intake might alter microbiota and
metabolic composition.
Certain soluble fermentable fibres are candidate pre
biotics34, and some other types of dietary fibre can be
prebiotic, provided that they are selectively utilized by the
host microbiota and promote health. Categorizing fibres
as prebiotics is complicated by the fact that a dietary fibre
can be a prebiotic in one host but not another. For exam
ple, cellulose can be considered a prebiotic in ruminants
but not in humans, as the latter’s intestinal microbiota
only poorly utilize β(1→4) linked d
 ‑glucose polysacchar
ides35. Furthermore, a substrate qualifying as a prebiotic
might also depend on the target site. For example, xylitol
can be considered as a prebiotic in the oral cavity, but has
not been shown to be prebiotic elsewhere16,18.
Among the first group of substances recognized for
their ability to influence gastrointestinal health were
the oligosaccharides present in human milk. Human milk
oligosaccharides (HMOs) are particularly important for
the development of the newborn baby’s intestinal micro
biota and metabolic and immunological systems, which
have consequences for health later in life36,37. Consumption
of mother’s milk containing these HMOs clearly increases
the proportion of HMO-consuming Bifidobacteriaceae
and Bacteroidaceae28. Bifidobacterium longum subsp.
infantis (B. infantis) is the only Bifidobacterium spp. that
has specifically evolved machinery to degrade the com
plete repertoire of HMOs. Other Bifidobacterium spp.
predominant in adults, mainly B. longum subsp. longum,
B. adolescentis and B. lactis, lack many of the enzymes
necessary to directly utilize HMOs effectively 38,39.
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Substances that
aﬀect the microbiome

Selective utilization
by host microorganisms

Prebiotic*

Not Prebiotic
Dietary
ﬁbre

CLAs and
PUFAs

Human milk
oligosaccharides

Oligosaccharides
e.g. FOS, Inulin,
GOS, MOS, XOS

Readily
fermentable

Phenolics and
phytochemicals

Less
fermentable

Antibiotics

Proteins
and fats

Probiotics

Vitamins

Figure 1 | Distinguishing what is considered
prebiotic| Gastroenterology
with the proposed
Naturea Reviews
& definition.
Hepatology
Prebiotics must be selectively utilized and have adequate evidence of health benefit for
the target host. Dietary prebiotics must not be degraded by the target host enzymes.
*The figure shows candidate as well as accepted prebiotics in that levels of evidence
currently vary, with FOS and GOS being the most researched prebiotics.CLA, conjugated
linoleic acid; PUFA, polyunsaturated fatty acid; FOS, fructooligosaccharides;
GOS, galactooligosaccharides; MOS, mannanoligosaccharide; XOS, xylooligosaccharide.

HMOs might indirectly affect composition of the
intestinal microbiota by modulating immune responses
and also have metabolism-independent mechanisms of
action in the infant gut 40. In particular, fucosylated and
sialylated HMOs can prevent adhesion of pathogens to the
intestinal epithelium through a competitive mechanism
that ultimately protects the neonate from infection41,42.
The main issues for this discussion are the following.
Is there evidence that HMOs confer a health benefit in
humans through the host’s microbiota selectively utiliz
ing them, and therefore fulfilling the prebiotic definition?
And if compounds equivalent to HMO (or bovine milk
oligosaccharides, BMOs) were to be produced by enzy
matic synthesis, fermentation or extraction, could they
still be considered as prebiotic?
The ability of HMOs, BMOs or synthesized compounds
to act as a substrate for the selective growth of beneficial
bacteria, such as Bifidobacterium spp., would be supportive
evidence of a prebiotic nature43. To confirm their status
as a prebiotic, a controlled human study showing selec
tive growth of bifidobacteria resulting in a health benefit
is also needed. However, the use of such compounds for
in vivo studies is limited to only a few reports. In one study,
a chemically synthesized compound, 2ʹ‑fucosyllactose
(2ʹFL), equivalent to the naturally occurring 2ʹFL in HMO,
was added to formula milk along with GOS. Although
safe for infants, the 2ʹFL treatment provided no net dif
ference in weight, length, head circumference and other
measures compared with human milk over a 4‑month
period44. In another study by the same group, infants
fed formula with 2ʹFL plus GOS had immune responses
similar to breast-fed infants in that both groups had lower
levels of inflammatory cytokines than infants fed formula
plus GOS45. However, effects on the microbiota were not
reported in this study. In a third study, 2ʹFL and another
synthesized HMO, lacto‑N‑neotetraose, were adminis
tered to adults46. The treatments were well tolerated and
led to an increase in abundance of Bifidobacterium spp.
Collectively, these studies provide an incomplete assess
ment of the prebiotic properties of these synthesized

versions of HMOs. Although 2ʹFL is utilized by B. infantis
as well as some strains of B. longum subsp. longum and
B. breve46,47, the ecological context (that is, infants versus
adults) might dictate whether these HMOs are indeed pre
biotic. Moreover, having structural equivalence to specific
HMOs does not infer functional equivalence to the con
stellation of HMOs in milk48. Thus, for now, it is a cceptable
to state that some HMOs are candidate prebiotics.
Plant polyphenols constitute a class of compounds
that can also meet the criteria of prebiotics, although far
more studies in the target host are required. An estim
ated 90–95% of dietary polyphenols are not absorbed in
the small intestine and, therefore, reach the colon49 where
they undergo extensive biotransformation by the colonic
microbiota. Increasing evidence indicates that health
benefits associated with polyphenol consumption depend
on microbial utilization and the metabolites produced,
rather than on parent compounds50.
This evidence expands the prebiotic concept beyond
non-digestible oligosaccharides such as FOS and GOS.
However, evidence for these emerging prebiotics is scarce
relative to the fructans and galactans16 and more studies
measuring health benefits are required to fulfil their
prebiotic status.

Prebiotic utilization and host health
As selective utilization of a prebiotic by host microorgan
isms is key to its physiological effects, metabolic results of
this utilization must, by deduction, be the main drivers.
Some organic acids, for example, are principal end prod
ucts of non-digestible carbohydrate or dietary fibre fer
mentation by host microorganisms. The main SCFAs
(≥95%) generated mostly in the colon (humans) and
caecum (rodents) as a result of several bacterial metabolic
pathways are acetate (two carbon, C2), propionate (C3))
and n‑butyrate (C4). These SCFAs are crucial for intestinal
health and their activity can subsequently influence sites
distant to the gut, with different SCFAs having varying
functions. SCFAs can modulate certain aspects of meta
bolic activity including colonocyte function, gut homeo
stasis, energy gain, the immune system, blood lipids,
appetite and renal physiology, as reviewed elsewhere16,51,52.
In a study published in 2017, 13C-labelling was used
to show that colonic-administered acetate, propionate
and butyrate were systemically available at 36%, 9% and
2%, respectively, with conversion of acetate into butyrate
(24%) by the colonic microbiota53. Bifidobacteria, often
stimulated by specific prebiotics, do not produce butyrate,
so a probable scenario is that cross-feeding by other bac
teria must have resulted in production of this SCFA.
Much has been reported about the benefits of butyrate in
the gut and beyond54, leading to the potential of known
butyrate producers such as Faecalibacterium prausnitzii,
Eubacterium rectale or Roseburia spp. as possible pro
biotics and, therefore, new prebiotic targets. By contrast,
in the vagina, butyrate formation is more equivocal as
2‑hydroxyisovalerate and γ‑hydroxybutyrate have been
associated with bacterial vaginosis55. Rather, lactic acid
production and an increase in IL‑10 levels might be
beneficial, indicating that prebiotics might be functional
in the vaginal environment, because of their effects in

NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY

ADVANCE ONLINE PUBLICATION | 5

.
d
e
v
r
e
s
e
r
s
t
h
g
i
r
l
l
A
.
e
r
u
t
a
N
r
e
g
n
i
r
p
S
f
o
t
r
a
p
,
d
e
t
i
m
i
L
s
r
e
h
s
i
l
b
u
P
n
a
l
l
i
m
c
a
M
7
1
0
2
©

C O N S E N S U S S TAT E M E N T
the gut 56. Lactulose, which has potential benefits in the
gut and vagina, can increase lactic acid levels and decrease
β‑glucuronidase activity, considered beneficial for the
host 57. Owing to the anatomical proximity of rectum to
vulva, some microorganisms capable of utilizing pre
biotics in the gut are also present in the vagina, including
Bifidobacterium and Lactobacillus spp.58–60.
Bile salt hydrolases are a family of enzymes prod
uced exclusively by enteric microorganisms as a form of
defence against their harsh, bile-rich environment. Bile
acid transformation and/or metabolism in the gut is per
formed by a number of species, including Lactobacillus,
with known beneficial effects on the host. Joyce & Gahan61
demonstrated that elevated bile salt hydrolase activity
could promote reduced weight gain in mice and influ
ence host pathways involved in lipid metabolism, periph
eral circadian rhythm, gut barrier function and immune
homeostasis. One study 62 showed that enhanced bacterial
deconjugation of taurine from primary bile acids occurred
in the presence of prebiotic inulin, supporting the theory
that faecal bile acid profiling might be a useful biomarker
for the intake of prebiotics in mice and potentially also
in humans.
The net result of prebiotic utilization within the gut
could also extend to health benefits elsewhere in the
body. For example, GOS stimulated growth of bifido
bacteria in the mouse gut led to modulation of cortical
IL‑1β and 5‑HT2A receptor expression and reduced anx
iety levels63, as well as enhancing brain barrier function in
obese mice64. Similarly, utilization of prebiotics might also
reduce blood ammonia levels and improve psychometric
tests in patients with hepatic encephalopathy 65, presum
ably through the formation of relevant bacterial metabo
lites. Study findings suggest that prebiotics can reduce
the development or severity of atopic dermatitis and
eczema in children, presumably mediated by alterations
to bacterial growth and interactions with the developing
immune system, beginning in the gut 66,67. The ability to
increase water retention on the skin and reduce erythema
formation is an emerging attribute of GOS ingestion, as
reported in mouse studies68. On the skin, application of a
prebiotic might stimulate changes in bacterial69 or fungal70
profiles perhaps by targeting epidermal growth f actor
receptor. The health consequences of this approach are
currently unclear, but might include psoriasis, acne,
dermatitis, eczema and wound development66,67,71.
Studies in mice have shown that oligofructose (a fruc
tan) reduced diet-induced obesity, diabetes, hepatic
steatosis and inflammation by mechanisms linked with
changes in specific gut microorganisms and meta
genomics functions of bacteria72. A study in rats suggested
that oligofructose consumption might normalize the
metabolomic signature of insulin resistance in obese rats
and reduce obesity in offspring 73. The ability to enhance
secretion of satiety hormones peptide YY and glucagon-
like peptide‑1 might be an associated attribute of p
 rebiotic
intervention and related SCFA production74–76.
In the mouth, compounds such as algal lectins, cran
berry juice and cocoa polyphenols have been used to
reduce the abundance of cariogenic bacteria. However,
these substrates do not function through being selectively

utilized by beneficial host microorganisms in the mouth,
so they are not prebiotics77. Short-chain GOS and longchain FOS have been administered orally with B. breve
and were found to increase peak expiratory flow and
reduce systemic production of type 2 T‑helper cytokines
after allergen challenge in adults with allergic asthma78.
The proposed mechanism, whereby microbial utilization
of GOS and FOS, presumably in the intestine, could lead
to immunological modulation that enabled the host to
cope better with allergen exposure in the lungs, was not
identified. In the nose and upper respiratory tract, bac
terial species can be manipulated by prebiotics to influ
ence health through immune reactions79 or competition
with aetiological agents of disease80.

Conferring a health benefit
The ultimate goal of any intervention, including pre
biotics, is to improve health and, therefore, reduce the
risk or burden of disease. The most effective approaches
are those that rely on prevention and recognize that
early-life strategies that promote a resilient, diverse and
healthy microbiota have greatest long-term potential to
benefit health81,82. Evidence for the important relationship
between the structure and function of the microbial com
munity, prebiotic use and host health has accumulated
rapidly over the past decade20,23,30. To satisfy the criterion
of conferring a health benefit, controlled studies estab
lishing direct links between the prebiotic and health are
needed in the target host. The level of evidence should
be commensurate with the strength of the health benefit
claim. To date, numerous randomized controlled t rials
have shown health benefits of a variety of prebiotics across
a range of populations, from healthy individuals to those
with acute and chronic diseases. These and other human
studies have been summarized elsewhere and are not dis
cussed in detail here, but key examples are listed in TABLE 1
(REFS 16,65,67,83–120).
Importantly, the effects of any intervention will be
affected by a variety of host and environmental factors121.
Thus, the effects of prebiotics have the potential to vary
widely on an individual basis. Microbial utilization of
prebiotics can only occur if the appropriate bacteria are
a component of the host’s microbiota. This aspect might
explain individual differences in responsiveness and in the
outcomes of clinical trials. Host factors include variation
in genetic predisposition to diseases (across multiple loci)
as well as specific polymorphisms in microbial recognition
pathways that can influence colonization and its biological
effects16. A number of environmental factors, including
mode of delivery and early feeding, antibiotics, disease
status and adult diet, can influence the human microbiome
and possibly the effects of prebiotic supplementation122–125.
Application to benefit animals
Prebiotics have been studied and used for companion
animals, livestock, poultry and aquaculture. The inherent
differences among animal species with regards to living
environment, anatomy and physiology, dietary composi
tion and reliance on the gut microbiota for energy, must
be considered when evaluating the effect of prebiotics on
animal health126.
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Table 1 | Health end points targeted in human trials of orally administered prebiotics
Health end point

Prebiotic used

Refs

Metabolic health: overweight and obesity; type 2 diabetes mellitus;
metabolic syndrome and dyslipidaemia; inflammation

Inulin, GOS, FOS

Satiety

FOS

75,76,90–92

Stimulation of neurochemical-producing bacteria in the gut

GOS

93,94

Improved absorption of calcium and other minerals, bone health

Inulin, FOS

Skin health, improved water retention and reduced erythema

GOS

100,101

Allergy

FOS, GOS

102–105

IBD

Inulin, lactulose

106

Urogenital health

GOS

107

Bowel habit and general gut health in infants

GOS, FOS,

108,109

Infections and vaccine response

FOS, GOS, polydextrose

110–114

Necrotizing enterocolitis in preterm infants

GOS, FOS

115

IBS

GOS

116

Traveller’s diarrhoea

GOS

Constipation

Inulin

118,119

Immune function in elderly individuals

GOS

56,120

22,74,75,83–90

95–99

117

FOS, fructooligosaccharides; GOS, galactooligosaccharides.
TABLE 2 provides examples of the use of prebiotics in
animals. Dogs and cats evolved as Carnivora eating diets
high in protein and fat but low in fibre126. They are non-
ruminants with short, simple gastrointestinal tracts that
have little capacity to ferment non-digestible substances,
which predominantly occurs in the colon126. Nevertheless,
some health benefits have been achieved with prebiotic
administration such as reduced infections, improved
insulin sensitivity and better faecal consistency 127–131.
Prebiotics such as oligosaccharides of fructose,
mannose and chitin protect piglets against high environ
mental stressors (such as antibiotics, etc.) and pathogen
loads, including faecal E. coli shedding, and reduced
infection-associated responses to Salmonella enterica
serovar Typhimurium infection or porcine r eproductive
and respiratory syndrome virus132–135.
Calves are born in a pre-ruminant state and func
tion as non-ruminants until the rumen and other com
partments of the stomach fully develop136. During the
first few weeks of life, or longer in the case of veal calves
maintained on low-roughage diets (that is, low in fibrous
material), prebiotics can be used to increase growth,
improve feed conversion ratio, reduce the incidence and
severity of scours (diarrhoea) or reduce the incidence of
respiratory diseases136–139.
Poultry, which are used primarily for the production
of meat or eggs, include landfowl (for example, chickens,
turkeys and quail) and waterfowl (for example, duck
or geese) species, respond to prebiotics despite most
having a fairly short midgut and hindgut that includes
a short, straight colon and twin caeca140. Dietary pre
biotics, including inulin, yeast cell wall extracts, lactulose
and GOS are usually fed at concentrations up to 0.2%
(weight/volume) of diet140–146.
Farmed aquatic species include finfish and shell
fish. Although anatomy varies among carnivorous

(for example, turbot), omnivorous (for example, cat
fish) and herbivorous (for example, sturgeon) species,
all fish have a fairly simplistic and short gastrointestinal
tract 147–149. The short length and simple structure (lack
of special adaptations) of the fish gut results in the rapid
transit of digested material, limiting the time available for
microbial or prebiotic activity. Effective prebiotic doses
in aquatic host species are typically in the range of 1–3%
(weight/volume) of diet147–149.
Horses are large non-ruminant herbivores that rely
heavily on microbial fermentation for energy, with more
than half of their maintenance energy requirement
coming from microbial fermentation occurring in their
enlarged caecum and colon126. As their typical diet is high
in roughage and feedstuffs that are consumed through
out the day, prebiotic interventions might help improve
effectiveness of fermentation150–152.

Guidance for stakeholders
Developing a consensus definition of prebiotic is use
ful for many stakeholders (FIG. 2), whose responsibilities
are discussed here. Agreement on this definition will
reduce misinformation and confusion among consumers
and health-care providers, facilitate sensible regulatory
approaches, and provide common terminology and scope
for future prebiotic research.
Consumers. This consensus definition should enable
consumers to understand the terms used on product
labels. Proper use of the terms by all stakeholders will
help avoid misleading messaging. Although consumers
might not be expected to understand the mechanistic
details for how prebiotics function to improve health,
our proposed definition should be readily appreciated.
Individuals can respond variably (due to their habit
ual diets, host microbiota, host genetics) to different
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Table 2 | Use of prebiotics in animals
Animal
species

Gastrointestinal tract
anatomy

Prebiotic used

Outcomes

Refs

Dog

Short, simple gastrointestinal
tract; hindgut (colonic)
fermentation

• scFOS (obese dogs)
• scFOS and MOS

• Improved insulin response
• Reduced pathogen infection

127–129

Cat

Short, simple
gastrointestinal; limited
hindgut fermentation

Fructans and galactans

Increased levels of organic acids, increased
bifidobacteria; modulation of glucose and
amino acids metabolism

130,131

Piglets

Caecal and colonic
fermentation

Soy polysaccharides, FOS,
chito‑oligosaccharides and MOS

Reduced pathogen load; improved growth

132–135

Pre-weaned Pre-ruminant state
calves

Cello-oligosaccharides, galactosyllactose, yeast cell wall extracts and MOS

Reduced pathogen load (gastrointestinal tract
and lung); improved weight gain

136–139

Poultry

Short midgut; hindgut
includes a short, straight
colon and twin caeca

Inulin, yeast cell wall extracts, lactulose
and GOS

Improved growth; reduced infection; improved
bone density and egg quality

140–146

Farmed fish

Simple, short gastrointestinal
tract

FOS, GOS and MOS

Improved survival rate; growth rate;
pathogen resistance

147–149

Horses

Substantial hind-gut
fermentation; large caecum,
colon

• Yeast cell fermentation products and
scFOS
• scFOS (obese horses)

• Increased nutrient digestibility; reduced faecal 150–152
pH levels and SCFA fluctuations in production
• Improved insulin sensitivity

FOS, fructo-oligosaccharides; GOS, galactooligosaccharides; MOS, mannanoligosaccharides; SCFA, short-chain fatty acid; scFOS, short-chain fructooligosaccharides.

prebiotics. This aspect dovetails with the concept of
individualized nutrition, which should be understood
by consumers.
Media and publishers of scientific papers. The media
(press, TV, web-based and others) should avoid use
of headlines that misrepresent results. Presentation of
association studies as if they contribute to an under
standing of causality can be especially misleading.
When discussing results of a single study, how
that study fits into the totality of evidence for that
topic should be reported, including null results. The
media should use the term prebiotic consistent with this
proposed definition.
Regulators. Regulators have primary responsibility for
ensuring safety of marketed products and protecting
consumers from fraudulent marketing. To accomplish
these goals, they are bound by statutes and regulations
adopted in their respective regions. Acceptance by regu
lators of the consensus definition of prebiotic would
make it clear what can be expected of these substances
from a scientific basis, and whether the term is being
used appropriately. For example, most prebiotics for the
gut require an oral dose of upwards of 3 g per day to
elicit an effect 16. Products containing doses lower than
this level should not be called prebiotics, unless such
a low dose has been proven to elicit selective effects
upon the microbiota and concomitant health aspects.
Incorporating a health benefit in the definition gives
a tangible end point for producers and regulators alike
to use in their assessment of whether a novel product
fulfils the criteria.
Scientists. Scientists have the responsibility of consider
ing all aspects of research on prebiotics (structural
biochemistry, clinically relevant end points, effective

dose, mechanisms of action, analytical methods) and
consolidating findings such that a clear description of
outcomes can be attained. Future prebiotic research
should strive to confirm causality between an observed
health benefit and microbiota-mediated mechanisms.
This confirmation of causality has been challenging to
achieve and some assumptions might be necessary, as is
the case for most pharmaceutical interventions. To this
end, well-controlled, placebo, blinded in vivo stud
ies that exploit the latest multi-omic technologies are
necessary. For example, in the case of a dietary prebiotic
for humans, a full assessment of gut microbiota changes
using robust molecular procedures that are fully and
accurately quantifiable is required, such that selective
substrate use can be ascertained. This analysis would
be coupled with metabolic assessments of f unctionality
(for example, metabonomics applied to blood, urine
and faeces). In patients, symptomology should be deter
mined, and in healthy or ‘at‑risk’ populations reliable
biomarkers of beneficial effects must be identified and
measured. These biomarkers could include immuno
logical changes, inflammatory mediators, serum lipid
levels, genotoxicity, toxicity and cognitive function,
among others, as appropriate to the study population.
The study population must be reflective of the condition
being researched, and an appropriate power calcula
tion used to determine volunteer n
 umbers. An effec
tive prebiotic dose and duration must be established to
compare effects. The test delivery vehicle (for example,
foods such as cereal, bread or juices) should be con
sidered such that prebiotic potential is not compro
mised. Exclusion and inclusion criteria are applied to
control for fluctuations in diet and other major lifestyle
changes. Following that, if the only discernible corre
lation is an improvement in health indices with selective
microbiota changes (composition and function) then it
could be assumed that two are inter-related and driven
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European Union. In the European Union (EU), any
health message carried by food requires assessment
of the science by the European Food Safety Authority
(EFSA) and authorization by the European Commission.
Suppliers or manufacturers of prebiotics. Suppliers Some prebiotic health claims have been approved,
and manufacturers have the responsibility to accurately for example chicory inulin153.
characterize the identity of their prebiotics and conduct
Inulin, FOS and GOS were used in the EU before
research to evaluate health benefits and safety. They 1997 and are considered safe food ingredients. However,
should be committed to high-quality, controlled, non- prebiotic substances created after 1997 are considered
biased studies that assess effects on clinically relevant novel and require safety clearance, a designation given,
outcomes with associated peer-reviewed publication of for example, to specific HMOs. To date, only one pre
the findings. They need to provide accurate technical biotic, chicory inulin, has received an EU health claim:
information to end-product manufacturers.
“Inulin improves bowel function” (REF. 153). This approval
was based on demonstration of a cause–effect relation
End-product manufacturers. Producers of consumer ship between consumption of the non-fractionated mix
products have a special responsibility to formulate ture of monosaccharides (<10% of total carbohydrate),
and label prebiotic products in a manner that is true disaccharides, inulin-type fructans and inulin extracted
to the definition proposed herein, does not overstate from chicory with a mean DP ≥9, and maintenance
the strength of evidence for health benefits and is con of normal defecation by increasing stool frequency.
sistent with dose and form used in efficacy studies. Additional product approvals hopefully will be forth
Producers can contribute by sponsoring research on coming, once relevant evidence is available, aided by the
health benefits of their final products. Advertising must contents of this consensus document.
be consistent with scientific definitions, not overstate the
When prebiotics are considered to be novel foods,
strength of evidence for health benefits and adhere to challenges arise to assessments as a food or individual
regulatory standards.
ingredient. The EU considers HMOs added to a food
as novel food ingredients, a legal construct determined
Health-care providers and standards or recommendation- by law 154. A FOS or GOS with a markedly altered DP
setting organizations. By providing compelling data that or with a different source or production method might
prebiotics can improve health, it is hoped that clinical be regarded as a novel food. An additional factor in the
organizations will accept and use the new definition, EU is the new consideration of safe history of use in
review the data in totality and develop evidence-based countries outside the EU154.
recommendations. This approach will help health-care
providers to make decisions about clinical use in the USA. Prebiotics is not yet a term recognized by the
absence of formal recommendations (based upon their FDA. Prebiotics are regulated based on the category
own risk–benefit analysis).
of product their intent and design dictates. Most pre
biotics are sold as ingredients for foods (including
Further regulatory considerations
infant formula) or are dietary ingredients in dietary
We anticipate that future prebiotic products will expand supplements. The FDA issued an updated guidance
current applications, include products administered to to industry on the new dietary ingredient notification
many body sites and be developed as non-conventional process in 2016 (REF. 155). Other regulatory categor
(or novel) foods, pharmaceuticals or other categories. ies that might apply to prebiotics are medical foods,
In this section further insights into regulatory consid drugs, cosmetics or devices developed for humans or
erations in two jurisdictions are provided as examples, animals. Changes to fibre labelling regulations in the
but the way that prebiotics are regulated will differ in USA in 2014 (in part owing to the different methods
other countries.
of analysis of fibre worldwide) will probably affect
carbohydrate-based prebiotics156.
In the past, various analytical methods deter
mined fibre levels in foods. Prebiotics, detected as
CHEC
soluble fibre, could be listed as fibre on the nutrition
KLI
——— ST
—
RADIO
Scientists
facts label. Under the new regulations, this listing will
——— —
——
———
——
TV
not be allowed. Fibre has been redefined to be sol
Suppliers
Regulators
NEWSPAPER
uble and insoluble non-digestible carbohydrates (with
ONLINE
three or more monomeric units) and lignin that are
intrinsic and intact in plants, and certain isolated and
Stakeholders in
Consumers
Media
prebiotic science
synthetic non-digestible carbohydrates (with three
or more monomeric units). Some prebiotics, such as
inulin, fall under the latter category, but even so were
not granted status as a fibre by the FDA. The new rules
Clinicians and
End-product
require that for a prebiotic to be listed as fibre, it must
recommendation-setting organizations
producers
confer a beneficial physiological effect and this evidence
must be submitted to the FDA either though the citizen
Figure 2 | Stakeholders with an interest in prebiotic science.
Nature Reviews | Gastroenterology & Hepatology
by the prebiotic. When communicating results, scien
tists should be careful to present data in a manner that
does not mislead readers.
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petition process or the health claims petition process
for the FDA to authorize the health claim. The FDA has
promised further guidance on this topic.

Conclusions
This paper describes conclusions of a consensus panel
of experts regarding a definition of prebiotic and the
rationale for that definition. It is hoped that this new
definition and explanation will clarify what is required
to call a substance a ‘prebiotic’. Given that differences
exist across animal species, prebiotic efficacy, safety
and appropriate dosing should be demonstrated for the
specific target host.
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